Complement C1s as a diagnostic marker and therapeutic target: Progress and propective.
Complement C1s as a diagnostic marker and therapeutic target: Progress and propective.
复制标题
补充 C1 作为诊断标志物和治疗靶点：进展和前景
DOI：
10.3389/fimmu.2022.1015128
复制
发表时间：
2022
影响因子：
7.3
通讯作者：
Xia S
中科院分区：
文献类型：
--
作者：
Ye J;Yang P;Yang Y;Xia S
补体系统的分子连接先天免疫和适应性免疫的效应子，并在维持体内平衡中发挥关键作用。其中，由C1q、C1r和C1s（C1qr2s2）组成的C1复合物是经典补体激活途径的起始物。虽然C1s的缺乏与早发性系统性红斑狼疮和对细菌感染的易感性增加有关，但C1r和C1s的功能获得性变体可能导致牙周Ehlers Danlos综合征。由于C1s在各种病理条件下被激活，并与炎症，自身免疫和癌症发展相关，因此它正在成为诊断和治疗各种疾病的信息生物标志物。因此，更敏感和方便的方法来评估的水平以及活性的C1s在临床样品是非常需要的。与此同时，已经开发了许多针对C1的小分子、肽和单克隆抗体。其中一些正在临床试验中进行评估，其中一种抗体已被美国FDA批准用于治疗冷凝集素病，一种自身免疫性溶血性贫血。本文就C1s的生物学特性、与疾病的发生发展和诊断的关系以及针对C1s的药物研究进展作一综述。这些进展说明C1s分子是一种有效的生物标志物和有前途的药物靶点。
The molecules of the complement system connect the effectors of innate and adaptive immunity and play critical roles in maintaining homeostasis. Among them, the C1 complex, composed of C1q, C1r, and C1s (C1qr2s2), is the initiator of the classical complement activation pathway. While deficiency of C1s is associated with early-onset systemic lupus erythematosus and increased susceptibility to bacteria infections, the gain-of- function variants of C1r and C1s may lead to periodontal Ehlers Danlos syndrome. As C1s is activated under various pathological conditions and associated with inflammation, autoimmunity, and cancer development, it is becoming an informative biomarker for the diagnosis and treatment of a variety of diseases. Thus, more sensitive and convenient methods for assessing the level as well as activity of C1s in clinic samples are highly desirable. Meanwhile, a number of small molecules, peptides, and monoclonal antibodies targeting C1s have been developed. Some of them are being evaluated in clinical trials and one of the antibodies has been approved by US FDA for the treatment of cold agglutinin disease, an autoimmune hemolytic anemia. In this review, we will summarize the biological properties of C1s, its association with development and diagnosis of diseases, and recent progress in developing drugs targeting C1s. These progress illustrate that the C1s molecule is an effective biomarker and promising drug target.
登录
查看更多内容
影响因子：
7.3
作者：
Gaboriaud C;Ling WL;Thielens NM;Bally I;Rossi V
通讯作者：
Rossi V
影响因子：
7.3
作者：
Bally, Isabelle;Dalonneau, Fabien;Gaboriaud, Christine
通讯作者：
Gaboriaud, Christine
DOI：
10.1073/pnas.1718709115
发表时间：
2018-01-23
影响因子：
11.1
作者：
Almitairi JOM;Venkatraman Girija U;Furze CM;Simpson-Gray X;Badakshi F;Marshall JE;Schwaeble WJ;Mitchell DA;Moody PCE;Wallis R
通讯作者：
Wallis R
影响因子：
4.6
作者：
Asavapanumas N;Tradtrantip L;Verkman AS
通讯作者：
Verkman AS
DOI：
10.1016/0167-4838(90)90169-g
发表时间：
1990-02-09
期刊：
BIOCHIMICA ET BIOPHYSICA ACTA
影响因子：
--
作者：
ERIKSSON, H;NISSEN, MH
通讯作者：
NISSEN, MH